Senti Bio to Present Updated SENTI-202 Clinical Data at ASH 2025, Showcasing Logic Gate Technology in AML Treatment
核心洞察
Senti Bio will present updated clinical results for SENTI-202, a first-in-class logic gated CAR-NK cell therapy, at the American Society of Hematology Annual Meeting in December 2025.
The therapy demonstrates deep and durable clinical remission rates with a strong safety profile in patients with relapsed/refractory acute myeloid leukemia.
SENTI-202's OR/NOT Logic Gate technology shows selective killing of leukemic blasts and stem cells while sparing healthy hematopoietic stem and progenitor cells.
Senti Biosciences will present updated clinical data for its first-in-class logic gated CAR-NK cell therapy SENTI-202 at the American Society of Hematology (ASH) Annual Meeting in December 2025, building on promising results in treating relapsed/refractory acute myeloid leukemia (AML). The presentations will showcase the potential of the company's Logic Gate technology to achieve selective cancer killing while sparing healthy tissue.
ASH Presentations Highlight Clinical Progress
The biotechnology company announced it will deliver two presentations at the 67th ASH Annual Meeting, including one oral presentation on December 8, 2025. The presentations will feature data from additional clinical trial participants and longer follow-up compared to previous reports, demonstrating deep and durable clinical remission rates combined with a strong safety profile.
"At ASH, we're thrilled to present an expanding body of evidence, with more patients and more follow-up data, that continues to demonstrate the potential for the industry's first cell therapy that makes complex, autonomous decisions to transform the relapsed/refractory AML treatment landscape," said Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences.
The oral presentation, titled "Promising results from an ongoing Phase I multicenter study of senti-202," will be delivered on December 8 at 5:45 PM in the OCCC Valencia Room. A companion poster session will present correlative data consistent with SENTI-202's clinical activity and unique logic gated mechanism of action.
Logic Gate Technology Demonstrates Selective Targeting
Pharmacodynamic data presented at ASH will further underscore clinical proof-of-mechanism for SENTI-202's 'OR/NOT' Logic Gate technology. The data shows selective killing of leukemic blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs).
SENTI-202 is designed with three main components: an OR GATE that recognizes and kills CD33 (搜索) and FLT3 (搜索) expressing cells, a NOT GATE that protects healthy cells expressing EMCN (搜索) even if they also express CD33 and/or FLT3, and calibrated-release IL-15 to increase cell persistence and activity.
"We designed our Logic Gate technology to kill AML cells displaying CD33 (搜索) OR FLT3 (搜索) cancer targets and to spare normal cells displaying the EMCN (搜索) healthy target even if they express CD33 and/or FLT3," Lu explained. By targeting either or both antigens, SENTI-202 is designed to effectively kill both leukemic blasts and leukemic stem cells, which constitute a difficult-to-eradicate reservoir of AML disease.
Addressing Significant Unmet Medical Need
The therapy targets a significant unmet medical need in relapsed/refractory AML, a disease with poor prognosis. According to the National Cancer Institute, an estimated 22,010 new cases of AML will occur in the United States in 2025, with a five-year survival rate of approximately 32.9% at diagnosis. For patients with relapsed/refractory AML, median overall survival is typically approximately five months.
Earlier this year, the U.S. Food and Drug Administration granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML. The company is currently enrolling adult patients with relapsed/refractory CD33 (搜索) and/or FLT3 (搜索) expressing hematologic malignancies in a Phase 1 clinical trial.
Financial Position and Development Progress
In its third quarter 2025 financial results, Senti Bio reported cash and cash equivalents of approximately $12.2 million as of September 30, 2025, compared to $48.3 million as of December 31, 2024. Research and development expenses increased to $10.5 million for the three months ended September 30, 2025, compared to $8.7 million in the same period of 2024, primarily due to increased external services and personnel-related expenses.
The company reported a net loss of $18.1 million, or $0.69 per basic and diluted share, for the third quarter of 2025. CEO Timothy Lu emphasized the team's focus on driving SENTI-202 clinical development forward, continuing to execute on the dose expansion phase and enrolling additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose.
"With important milestones achieved in the third quarter, we continue to execute on our dose expansion phase and on enrolling additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose," Lu commented. The company plans to host a live webcast during the ASH meeting to discuss the results in detail.